Cytosorbents Corp

Cytosorbents Corp develops blood purification and adsorption devices used in critical care, cardiac surgery, and other acute care settings. Its lead product, CytoSorb, is sold in many countries outside the U.S., while the company is also pursuing regulatory approvals for DrugSorb-ATR and other product candidates in North America.

−36,5 %

71,5 %

−22,1 %

+4,1 %

2.13

1.58

— Cytosorbents Corp
%
CytoSorb therapy70% Hemoadsorption cartridges used in critical care and cardiothoracic surgery to remove inflammatory mediators and selected substances from blood.
DrugSorb-ATR10% A product candidate designed to remove antithrombotic drugs around surgery to reduce bleeding risk.
Other human devices10% Includes ECOS-300CY, PuriFi and related device offerings used with extracorporeal blood treatment systems.
Veterinary products5% VetResQ products used in animal critical care and veterinary applications.
Services and support5% Regulatory, clinical, and commercialization support tied to product adoption and market expansion.

The company sells primarily to hospitals, intensive care units, and cardiac surgery teams that use its devices in...

  • Critical care hospitalsprimary

    Buy CytoSorb for ICU patients with sepsis, septic shock, respiratory failure, and other acute inflammatory conditions.

  • Cardiothoracic surgery centersprimary

    Use CytoSorb or DrugSorb-ATR-related therapies to manage bleeding and drug-removal needs around surgery.

  • Physicians and clinical adoptersprimary

    Influence purchasing by adopting the therapy, generating clinical evidence, and driving protocol inclusion.

  • Payers and reimbursement decision-makerssecondary

    Assess whether the therapy is reimbursed and economically justified, affecting adoption speed.

  • Veterinary customersemerging

    Buy VetResQ for animal critical care use, a smaller but strategically relevant niche.

CytoSorbents is headquartered in Princeton, New Jersey, but its commercial footprint is international, with CytoSorb...

  • •Headquartered in Princeton, New Jersey, United States
  • •CytoSorb sold in more than 70 countries worldwide
  • •European Union is the core approved market for CytoSorb
  • •U.S. commercialization depends on FDA authorization for key products
  • •Canada commercialization is tied to Health Canada review of DrugSorb-ATR

Management is focused on expanding commercial adoption while advancing regulatory approvals for DrugSorb-ATR in the U.S...

01
U.S. regulatory approval for DrugSorb-ATRshort-term

Approval would unlock a large new market and materially improve commercialization prospects.

02
Cost reduction and operating disciplineshort-term

Lower spending is needed to preserve liquidity and reach cash-flow breakeven.

03
Clinical and market adoption expansionmedium-term

Broader physician acceptance and guideline inclusion are needed for sustained sales growth.

04
International commercialization of CytoSorbmedium-term

The company already has regulatory access in Europe and many other countries, which remains its main revenue base.

The company is highly exposed to regulatory outcomes, especially for DrugSorb-ATR in the U.S...

high

Regulatory failure for DrugSorb-ATR

The product candidate needs FDA and Health Canada authorization before meaningful North American sales can begin.

Scope
U.S. and Canada growth
Materiality
high
high

Market acceptance risk

Hospitals and clinicians may not adopt the devices without sufficient evidence, reimbursement, and guideline support.

Scope
CytoSorb and new product launches
Materiality
high
high

Financing and going-concern risk

Cash resources and operating losses create dependence on external funding and cost reductions.

Scope
Corporate liquidity
Materiality
high
medium

Competitive and reimbursement pressure

Competing technologies or unfavorable payer policies could reduce adoption and pricing power.

Scope
Global commercial markets
Materiality
medium
medium

Nasdaq listing compliance

Failure to meet listing standards could hurt stock liquidity and investor access to capital.

Scope
Public equity market access
Materiality
medium
Revenue recognition
Affects quarterly comparability and growth rates
Going-concern assessment
Signals financing dependence and potential dilution
Restructuring charges
Impacts operating expenses and short-term earnings
Stock-based compensation
Non-cash expense affects profitability trends
Royalty expense
Affects gross margin and operating leverage

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

CytoDyn Inc.

CYDY · Pharmaceutical Preparations

CYTOKINETICS INC

CYTK · Pharmaceutical Preparations

Sigyn Therapeutics, Inc.

SIGY · Surgical & Medical Instruments & Apparatus

AETHLON MEDICAL INC

AEMD · Surgical & Medical Instruments & Apparatus

aTYR PHARMA INC

ATYR · Biological Products, (No Diagnostic Substances)

: 28/04/2026